Protalix BioTherapeutics, Inc.

PLX · NYSE American · United States

Share price · PLX

$3.02+0.68 (+29.06%) 3M

close as of 2026-11-18 · 24h delayed · vol 963K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PLX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+9.4%
  2. 10 Nov 2026+11.3%
  3. 14 Aug 2026-5.9%

    Nothing announced by PLX that day or the session before.

  4. 13 Aug 2026-9.9%
  5. 12 Aug 2026+7.8%
  6. 18 Jun 2026+9.9%

    Nothing announced by PLX that day or the session before.

  7. 5 May 2026-8.0%

    Nothing announced by PLX that day or the session before.

  8. 18 Mar 2026-20.8%
  9. 11 Feb 2026+8.1%
  10. 2 Feb 2026+11.1%

Share of unusual movement by asset

For each asset, the share of PLX's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Alpha-galactosidase A (GLA / α-Gal A)Protein / enzyme therapeutic
Fabry Disease
Phase 2
Uric acidProtein / enzyme therapeutic
Gout
Severe Refractory Gout

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
pegunigalsidase alfaPhase 2/3Fabry Disease
Est. primary completion 2027-10 · NCT05710692 · CT.gov ↗
What to watch
December 2027 (1)
PRX-115Phase 2Gout
Est. primary completion 2027-12 · NCT07280156 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
pegunigalsidase alfaPhase 2/3Fabry Disease
Est. primary completion 2028-10 · NCT06328608 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$22M$6.9M$22M—$3.9M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$20M$4.3M$27M—-$10M operating cash flowreport ↗
2026-Q1$34M$5.4M$41M—$22M operating cash flowreport ↗
2025-Q3$18M$4.5M$14M—-$3.7M operating cash flowreport ↗
2025-Q2$16M$6.0M$18M—-$5.2M operating cash flowreport ↗
2025-Q1$10M$3.5M$19M$3.6M-$5.1M operating cash flowreport ↗
2024-Q3$18M$3.0M$27M—$4.1M operating cash flowreport ↗
2024-Q2$13M$3.0M$23M$2.2M-$3.6M operating cash flowreport ↗
2024-Q1$3.8M$2.9M$27M$4.6M$4.2M operating cash flowreport ↗
2023-Q3$10M$3.7M$20M$1.9M-$6.9M operating cash flowreport ↗
2023-Q2$35M$4.5M$48M—$5.0M operating cash flowreport ↗
2023-Q1$9.6M$5.8M$33M$3.1M-$3.0M operating cash flowreport ↗
2022-Q3$14M$7.4M$11M$3.6M-$9.2M operating cash flowreport ↗
2022-Q2$8.8M$7.6M$12M$5.3M-$7.4M operating cash flowreport ↗
2022-Q1$16M$8.8M$17M$2.3M-$5.8M operating cash flowreport ↗
2021-Q3$12M$7.3M$11M$4.2M-$1.9M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$53M$20M$15M$1.6M-$12M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$53M$13M$20M—$8.7M operating cash flowreport ↗
2023-FY$65M$17M$24M—-$1.3M operating cash flowreport ↗
2022-FY$48M$29M$17M$3.7M-$25M operating cash flowreport ↗
2021-FY$38M$30M$39M$6.9M-$10M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($101K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-03Schwartz Aharon · directorAward / grant (derivative)17,000——Form 4
2026-09-03Schwartz Aharon · directorAward / grant (derivative)8,500——Form 4
2026-09-03Forster Eliot · directorAward / grant (derivative)17,000——Form 4
2026-09-03Ben Zvi Shmuel · directorAward / grant (derivative)17,000——Form 4
2026-09-03Bar-Shalev Amos · directorAward / grant (derivative)17,000——Form 4
2026-09-03Bashan Dror · director, PRESIDENT AND CEOAward / grant (derivative)320,000——Form 4
2026-09-03Boudes Pol F · directorAward / grant (derivative)17,000——Form 4
2026-09-03Melincoff Gwen A · directorAward / grant (derivative)17,000——Form 4